{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:18:49Z","timestamp":1791829129392,"version":"4.3.4"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/med.0b013e3283631809","type":"journal-article","created":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T11:18:39Z","timestamp":1372245519000},"page":"330-334","source":"Crossref","is-referenced-by-count":36,"title":["Update in the medical therapy of Cushing's disease"],"prefix":"10.1097","volume":"20","author":[{"given":"Lynnette K.","family":"Nieman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20211004","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrendo.2011.12","article-title":"Medscape, Management of Cushing disease.","volume":"7","author":"Tritos","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"R2-12-20211004","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors.","volume":"89","author":"Pivonello","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-12-20211004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushings disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-12-20211004","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushings disease.","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"R5-12-20211004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11102-011-0309-0","article-title":"Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report.","volume":"15","author":"Manavela","year":"2012","journal-title":"Pituitary"},{"key":"R6-12-20211004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushings disease.","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"key":"R8-12-20211004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1677\/JME-08-0162","article-title":"The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology.","volume":"42","author":"Ferone","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"R9-12-20211004","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multiligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"R10-12-20211004","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"Pasireotide B2305 Study GroupA 12-month phase 3 study of pasireotide in Cushings disease.","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"R14-12-20211004","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushings disease.","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"key":"R15-12-20211004","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1172\/JCI11098","article-title":"Retinoic acid prevents experimental Cushing syndrome.","volume":"108","author":"Paez-Pereda","year":"2001","journal-title":"J Clin Invest"},{"key":"R16-12-20211004","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/en.2006-0414","article-title":"Retinoic acid as a novel medical therapy for Cushings disease in dogs.","volume":"147","author":"Castillo","year":"2006","journal-title":"Endocrinology"},{"key":"R17-12-20211004","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2012-2328","article-title":"Potential role for retinoic acid in patients with Cushings disease.","volume":"97","author":"Pecori Giraldi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-12-20211004","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","article-title":"Successful treatment of Cushings syndrome with the glucocorticoid antagonist RU 486.","volume":"61","author":"Nieman","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-12-20211004","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushings syndrome.","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-12-20211004","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1023\/A:1025725716343","article-title":"Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.","volume":"25","author":"Jang","year":"1997","journal-title":"J Pharmacokinet Biopharm"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01266029-201308000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T06:28:47Z","timestamp":1633501727000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01266029-201308000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0b013e3283631809","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}